Overcoming subjectivity in assessing facial lipoatrophy: Is there a role for three-dimensional laser scans?

HIV Medicine

Volumn 4, Issue 4, 2003, Pages 325-331

  Benn, Paul ^a   Ruff, C ^a   Cartledge, J ^a   Sauret, V ^a   Copas, A ^b   Linney, A ^a   Williams, I G ^b   Smith, C ^b   Edwards, S G ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

3D surface laser scans; Facial lipoatrophy; HIV 1; Interobserver variability; Reproducibility

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADULT; ARTICLE; BODY MASS; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FACE DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMAGE PROCESSING; INCIDENCE; INTERMETHOD COMPARISON; LASER; LIPOATROPHY; MALE; MEASUREMENT; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; OUTPATIENT DEPARTMENT; PATIENT ATTITUDE; PATIENT MONITORING; PHYSICIAN ATTITUDE; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; REPRODUCIBILITY; SELF REPORT; THREE DIMENSIONAL IMAGING; UNITED KINGDOM; VIRUS LOAD;

ADULT; BODY MASS INDEX; FACE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; IMAGING, THREE-DIMENSIONAL; LASERS; MALE; MIDDLE AGED; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0142186261     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2003.00167.x     Document Type: Article

References (20)

1. Mocroff A, Villa S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Eurosida Study Group. Lancet 1998; 352: 1725-1730.
2. Christeff N, Melchiou JC, de Truchis P et al. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999; 13: 2251-2260.
3. Kotler DP, Rosenbaum K, Wang J et al. Studies of body composition and fat redistribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 228-237.
4. Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-1667.
5. Carr A, Samaras K, Thonsdottir A et al. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet 1999; 353: 2893-2899.
6. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
7. McGowan I, Cheng A, Coleman S et al. Assessment of bone mineral density (BMD) in HIV-infected antiretroviral-therapy-naïve patients. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 628].
8. Knobel H, Guelar A, Valdecillo I et al. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 629].
9. Chang K, Kim J, Hong S et al. Does race influence bone mineral density in HIV-infected individuals receiving HAART? 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 630].
10. Carr A, Eismann JA, Miller J et al. Lactic acidaemia is associated with spinal osteopenia in HIV infected men. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 631].
11. Tebas P, Claxton S, Monoy K et al. Lack of association between visceral adiposity and osteopenia in HIV-infected individuals. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 633].
12. Carter VM, Hoy JF, Bailey M et al. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med 2001; 2: 174-180.
13. Mauss S, Corillius M, Wolf E et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med 2002; 3: 49-55.
14. Gatti AM, Guaraldi G, Migliorino G et al. Patient-clinician concordance on lipodystrophy severity. Antiviral Ther 2002; 7: 64.
15. Carr A, for the HIV Lipodystrophy Case Definition Group. An objective case definition for HIV lipodystrophy. Lancet 2003; 361: 726-735.
16. Viciana P, Lopez-Cortes F, Alarcon A et al. Facial lipoatrophy associated with HAART: usefulness of cheek measurement and factors associated. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 645].
17. Bhatia G, Vannier MW, Smith KE et al. Quantification of facial surface change using a structured light scanner. Plast Reconstr Sury 1994; 94: 768-774.
18. Yamada T, Sugahara T, Mori Y et al. Rapid three-dimensional measuring system for facial surface structure. Plast Reconstr Surg 1998; 102: 2108-2113.
19. Bush K, Antonyshyn O. Three-dimensional facial anthropometry using a laser surface scanner: validation of the technique. Plast Reconstr Surg 1996; 98: 226-235.
20. Wilson I, Snape L, Fright R et al. An investigation of laser-scanning techniques for quantifying changes in facial soft-tissue. NZ Dent J 1997; 93: 110-113.